News

Video

The Impact of Real-World Evidence on the Treatment of Patients With Advanced Endometrial Cancer

Author(s):

Floor J. Backes, MD,Matthew A. Powell, MD, Washington University in St. Louis

Matthew Powell, MD, and Floor Backes, MD, discuss real-world evidence from recent trials confirming benefit of immunotherapies in practice for patients with advanced endometrial cancer.

Related Videos
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Kathleen N. Moore, MD, MS
Matthew Powell, MD
Alberto Montero, MD, MBA, CPHQ
Related Content
Cervical Cancer| lertsakwiman – stock.adobe.com
January 6th 2025

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center
December 28th 2024

Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Lunresertib Plus Camonsertib in Endometrial, Ovarian Cancer | Image Credit: © Katsyarina - stock.adobe.com
December 19th 2024

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

stock.adobe.com
December 16th 2024

Dostarlimab Plus Chemo Earns Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer